The CMT Research Foundation unites the voices of patients, researchers, pharma companies, and regulatory agencies to develop treatments for CMT.

This event takes place over two days. Friday is a scientific meeting and is meant for researchers and scientists working in CMT. Saturday is primarily for patients and their families and caregivers, providing a chance to interact with the research community that is working so hard on their behalf and to better understand the latest in research progress.

For the Scientific Community

September 22nd

A day for researchers, industry and government agencies to:

 SHARE the latest in CMT drug development research

CREATE new connections and collaborations

EXAMINE the most pressing issues facing CMT drug development


Click here to see the full agenda


Click here to see the full day of event agenda

Chris Austin, MD, PhD

CEO-Partner of Flagship Pioneering,
Chief Executive Officer of Vesalius Therapeutics and
Founding Director of the National Center for Advancing Translational Sciences (NCATS)

Vera Fridman

University of Colorado

Rudolf Martini

University of Würzbug

Rachel Bailey

University of Texas Southwestern Medical Center

For the Patient Community

September 23rd

A day for the patient community to:

LEARN about the latest developments and clinical trials in CMT

INTERACT with distinguished scientific experts and clinicians

ACT to speed treatments for patients and families

Click here to see the full agenda


Click here to see the full day of event agenda

Reza Seyedsadjadi, MD

Director, Charcot-Marie-Tooth (CMT) Center of Excellence, Massachusetts General Hospital
Assistant Professor of Neurology, Harvard Medical School

David Herrmann, MBBCh

Director, Charcot-Marie-Tooth (CMT) Center of Excellence, University of Rochester
Professor Department of Neurology, University of Rochester

Jim Lupski

Baylor College of Medicine

Katie Moss

Johns Hopkins University

Thomas Pedersen

NMD Pharma

Book your stay at the Royal Sonesta Boston with our special room rate here.












  Thank You to Our Sponsors!

The Scientific Programming Committee

Marina Kennerson, PhD

Professor of Neurogenetics and Neuroscience

ANZAC Research Institute and University of Sydney, Australia

Charles Abrams, MD, PhD

Professor of Neurology and Rehabilitation

University of Illinois, Chicago (UIC)

Edritz Javelosa, PhD

Research Portfolio Director 

Muscular Dystrophy Association

Paul August, PhD

Chief Scientific Officer

ReviR Therapeutics

Amanda Haidet-Phillips, PhD

Senior Director, Translational Medicine

Novartis Institutes for BioMedical Research

Dennis Klein, PhD

Research Scientist, Department of Neurology

University Hospital Wuerzburg, Germany

Glen Nuckolls, PhD

Program Director, Neurogenetics, Division of Neuroscience

U.S. National Institute of Neurological Disorders and Stroke (NINDS)

Tiina Urv, PhD

Program Director, Office of Rare Diseases Research

U.S. National Center for Advancing Translational Sciences (NCATS)

Alessandra Bolino, PhD

Group Leader, Human Inherited Neuropathies Unit 

San Raffaele Scientific Institute, Milan, Italy 

If you have any questions please contact Vanessa Sanchez at

[email protected] or +1 (404) 474-8805